RxDoctor Payments Data

Katherine Trawinski

Family · Depew, NYNPI 1215693072

Payments from drug & device makers

$1,769in general payments, 2019–2025

Across 68 payments — averaging $26.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$227
  • Kiniksa Pharmaceuticals, Ltd.$151
  • Boehringer Ingelheim$143
  • AstraZeneca$138
  • Boston Scientific$120
  • Novo Nordisk$108
  • plus $881 from 25 others

What the payments were for

  • Food & beverage$1,769100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,769 in reported general payments places this provider in the 80th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$16,404
Medicare patients
100
Services billed
215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide36$45,860
OzempicSemaglutide33$38,899
EliquisApixaban24$20,719
JardianceEmpagliflozin20$19,170
XareltoRivaroxaban14$16,916
TrulicityDulaglutide12$13,238
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,776
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,396
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$4,670
Levothyroxine Sodium124$2,169
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,124
Fluoxetine Hcl15$1,572
Atorvastatin Calcium95$1,469
PaxlovidNirmatrelvir/Ritonavir13$1,410
Omeprazole75$1,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$227$59,09848 claims
Novo NordiskOzempic$108$38,89933 claims
PfizerEliquis, Paxlovid$52$22,12937 claims
Boehringer IngelheimJardiance$143$19,17020 claims
Johnson & JohnsonXarelto$61$16,91614 claims
GSKTrelegy Ellipta, Anoro Ellipta$47$15,17227 claims
AbbVieSynthroid$26$1,26013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,883 family providers in New York.

Other family in Depew

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →